CHARTWELL INJECTABLE
GenericsCHARTWELL INJECTABLE is a generic drug manufacturer focused on Respiratory, Infectious Disease, Cardiovascular.
CHARTWELL INJECTABLE's Key Drugs
CHARTWELL INJECTABLE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
CHARTWELL INJECTABLE's Recent FDA Approvals
New NDA/BLA approvals for CHARTWELL INJECTABLE over the last two years — novel drugs only, excluding generics and label supplements.
CHARTWELL INJECTABLE's Therapeutic Areas
CHARTWELL INJECTABLE's approved drugs and pipeline span 4 therapeutic areas, led by Respiratory and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CHARTWELL INJECTABLE's Top Competitors
CHARTWELL INJECTABLE's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Merck, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
CHARTWELL INJECTABLE Pipeline Snapshot
Active clinical trials for CHARTWELL INJECTABLE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1997-04-22
- Latest
- 2011-04-08
- Applications
- 6